20:49 , Oct 13, 2017 |  BioCentury  |  Emerging Company Profile

CBT’s silk road

While several Chinese biotechs have adopted a business model in which they in-license Western assets to develop for the China market, U.S.-based CBT Pharmaceuticals Inc. is doing the reverse, sourcing innovative Chinese assets to develop...
07:00 , Aug 30, 2016 |  BC Extra  |  Financial News

CBT raises $9.8M in series A

Cancer company CBT Pharmaceuticals Inc. (Santa Clara, Calif.) raised $9.8 million in a series A round led by OrbiMed Asia. CBT's parent company is CRO Crown Bioscience International Inc. (TPex-E:6554), which seeded the biotech with...